Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 8/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6973538 | 1.00 | FAP (0.46) | FAPESR2PTPN1DPP4HDAC8 | |
| SCHEMBL5202232 | 0.89 | HDAC8 (0.47) | FAPPTPN1DPP4HDAC8DPP8 | |
| SCHEMBL5206014 | 0.89 | FAP (0.52) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL5206796 | 0.86 | DPP4 (0.44) | FAPPTPN1DPP4DPP8DPP9 | |
| SCHEMBL5208196 | 0.85 | HDAC8 (0.50) | FAPDPP4HDAC8 | |
| SCHEMBL7988406 | 0.83 | DPP4 (0.48) | FAPESR2PTPN1DPP4HDAC8 | |
| SCHEMBL7988401 | 0.83 | DPP4 (0.48) | FAPESR2PTPN1DPP4HDAC8 | |
| SCHEMBL864823 | 0.76 | PTPN1 (0.54) | ESR2PTPN1HDAC8 | |
| SCHEMBL30254985 | 0.76 | PTPN1 (0.54) | ESR2PTPN1HDAC8 | |
| SCHEMBL29502321 | 0.76 | PTPN1 (0.54) | ESR2PTPN1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| EP-1746086-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1333025-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072892-A1 | Cyanopyrrolidine derivatives | CCR9, OPRD1, CBR1 | FAP 3334/4885ESR2 2062/4885PTPN1 1331/4885 |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | DPP4, DPP9, DPP3 | FAP 40/4885ESR2 3353/4885PTPN1 2183/4885 |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | CBR3, CBR1, TERT | FAP 2348/4885ESR2 2519/4885PTPN1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.